Banning Gain-of-Function Research Would Do Far More Harm Than Good A House-passed bill could stifle the potential for revolutionary medical advancements Mar 11, 2024
Investigational Immunotherapy Combo Shows Promise for Advanced Solid Tumors Objective response rate of 37.7% in patients with various solid tumors in phase I study Feb 26, 2024
Transforming Shots Into Pills; 'Tip of the Iceberg' for TILs? Food Additives Warning News, features, and commentary about cancer-related issues Feb 23, 2024
Make the Diagnosis: A Blue-Black Facial Nodule -- What's Your Best Guess? A 64-year-old postal worker visited his doctor about a lesion that he first noticed on his face 2 months prior. Can you diagnose the patient? Feb 23, 2024
FDA OKs First Cellular Therapy for Melanoma Lifileucel approved as treatment for advanced melanoma after anti-PD-1 and targeted therapy Feb 16, 2024
Rush to Publish? Medicare Drug Plan Lawsuit Quashed; Activity Curbs Cancer Pain News, features, and commentary about cancer-related issues Feb 16, 2024
Immunotherapy May Hold Promise for Skin Cancers After Kidney Transplant Two studies had "important differences," but can help guide clinicians Feb 13, 2024
No Relief From Drug Shortages; New Lymphedema Guideline; A 'Good' Patient No More News, features, and commentary about cancer-related issues Feb 09, 2024
Smoking Tied to Increased Mortality From Early-Stage Melanoma Association only see among current smokers, however Feb 06, 2024
Progress in Early Cancer Diagnosis; Breast Cancer in Younger Women; Diet and Cancer News, features, and commentary about cancer-related issues Feb 02, 2024
No Cervical Cancer After HPV Vax; Brain Tumor Blood Test; Weight Loss and Cancer News, features, and commentary about cancer-related issues Jan 26, 2024
FDA Clears AI-Powered Non-Invasive Skin Cancer Detector Intended for use in primary care, handheld device is first of its kind Jan 17, 2024
Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA News, features, and commentary about cancer-related issues Jan 12, 2024
Language Minimizing Adverse Events; HPV and Thyroid Cancer; Ultrasound Bras News, features, and commentary about cancer-related issues Jan 05, 2024
Futile Immunotherapy for Cancer Grows More Common Occurs most often at non-academic and low-volume centers Jan 04, 2024
Another CAR-T Warning; 'Sweet' Cancer Test; 'Molecular Jackhammer' Blows Up Cancer News, features, and commentary about cancer-related issues Dec 28, 2023
Vitamin D for Neuropathy; Good & Bad News for CAR-T; New Labeling for Surgical Mesh News, features, and commentary about cancer-related issues Nov 10, 2023
Wearables as Cancer Monitors; No China Price Break; Cancer Mystery in Appalachia News, features, and commentary about cancer-related issues Nov 03, 2023
Soap to Fight Skin Cancer; $1,000 Early Cancer Detection Test; FDA Approval in MDS News, features, and commentary about cancer-related issues Oct 27, 2023
Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC Follow-up results from phase II study show 12-month EFS rate of 89% in stage II-IV disease Oct 25, 2023
Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years And early ctDNA reductions correlated with survival Oct 21, 2023
Lonely Cancer Deaths; Virtual Reality for Pain; 3D Models May Improve Treatment News, features, and commentary about cancer-related issues Oct 19, 2023
Cancer Drug Shortages for Kids; Pharma Agrees to Price Talks; Catch-Up on Screening News, features, and commentary about cancer-related issues Sep 28, 2023
TikTok Dinged for Misinformation; BRCA Risk Overestimated; Cheers for Oncology News, features, and commentary about cancer-related issues Sep 21, 2023
Cisplatin Shortage Eases; Air Pollution Linked to Breast Cancer; Pap Test Confusion News, features, and commentary about cancer-related issues Sep 15, 2023
What to Know About Merkel Cell Carcinoma, the Rare Cancer That Killed Jimmy Buffett An expert weighs in on what to know about the uncommon skin cancer Sep 06, 2023
Jill Biden Has COVID; BA.2.86 Less Evasive Than Feared? Jimmy Buffett's Fatal Cancer Health news and commentary from around the Web gathered by ѿapp staff Sep 05, 2023
Gut Microbiome Study Yields Clues to Melanoma Development, Progression Differences between patients and volunteers, early- vs late-stage may help guide management Aug 31, 2023
Study Reinforces BRAF-MEK Inhibition Over Anti-BRAF Only in Advanced Melanoma Improved PFS with encorafenib-binimetinib versus encorafenib, but immunotherapy still top option Aug 29, 2023
Mohs Surgery Best for Early-Stage Merkel Cell Carcinoma? Retrospective data suggest superior survival in pathologically confirmed node-negative disease Aug 23, 2023
FDA OKs First Liver-Directed Treatment for Metastatic Uveal Melanoma Hepzato Kit melphalan delivery system produced objective responses in 36% of patients Aug 15, 2023
Adjuvant Nivolumab Promising in Resected Merkel Cell Carcinoma Absolute risk reduction of 9-10% in 1- and 2-year DFS compared with observation Jul 14, 2023
Dermatologists Hone Diagnostic Accuracy for Suspect Lesions With AI 'Collaboration' Sensitivity, specificity, mean accuracy, and AUC improved significantly with neural network input May 16, 2023
Allo-Transplant Tied to Better PFS in Advanced Cutaneous T-Cell Lymphomas Results will likely "encourage a practice change," editorialists say May 10, 2023
Responses to PD-1 Blockade Approach 90% in Rare Melanoma "One of the highest tumor response rates we've seen in any cancer," study discussant says Apr 17, 2023
Personalized Cancer Vaccine Boosts Recurrence-Free Survival in Melanoma Clinical implications apply to virtually all solid tumors and possibly hematologic malignancies Apr 17, 2023
FDA OKs Another PD-1 Inhibitor for Merkel Cell Carcinoma Retifanlimab produced responses in 52% of patients with untreated unresectable disease Mar 22, 2023
Vitamin B3 Doesn't Cut Skin Cancer Risk After Organ Transplant Randomized study finds no benefit with 12 months of nicotinamide versus placebo Mar 01, 2023
Long-Term Data Reinforce Targeted Combo Versus Single Agent for Advanced Melanoma Encorafenib-binimetinib tops vemurafenib, but checkpoint inhibitors remain first-line choice Dec 19, 2022
Xeljanz Cancer Risks Detailed New paper provides full results from ORAL Surveillance trial Dec 07, 2022
